XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 34.39

+6.7%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Olu Emuleomo who started this subject	8/22/2002 8:20:37 PM
From: aknahow	of 17367

Interesting how some ignore the facts and glibly post that Xoma has failed at everything. Some are very impressed with cash balances but have no idea of how to value a partnership agreement. That is especially true when the agreement is complex. Just what is a 10 year partnership that requires two indications in clinic for the life of the partnership? There are three levels of milestone payments which depend on the size of the indication. And we know that Xoma's share of gross profits is around 40% With the focus on Raptiva, where Xoma's U.S. share is 25% for which it paid only 12.5% of cost, few even remember the Baxter deal. It is worth checking out. sec.gov

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next